New enterprise: Nutraceutical company launches new products

Lexington, SC-A new research-based, ophthalmic nutraceutical company founded by one of the leading ophthalmologists in the United States has launched its line of nutraceutical products to optimize eye and body health.

Related Videos

Related Content

Kriya announces exclusive license, collaboration, agreement with Everads to advance gene therapies for diseases in ophthalmology, Including GA

September 28th 2023

EyePod: Transforming the MIGS pipeline into clinical reality

September 26th 2023

David Huang, MD, PhD, receives Lasker Award for transformative imaging technology

September 28th 2023

EyePod: Week in Review - September 17, 2023

September 23rd 2023

FDA approves RYZUMVI (Phentolamine Ophthalmic Solution) for the treatment of pharmacologically-induced mydriasis

September 27th 2023

Thea Pharma rolls out latanoprost ophthalmic solution 0.005% in the US

September 27th 2023

Kriya announces exclusive license, collaboration, agreement with Everads to advance gene therapies for diseases in ophthalmology, Including GA

September 28th 2023

EyePod: Transforming the MIGS pipeline into clinical reality

September 26th 2023

David Huang, MD, PhD, receives Lasker Award for transformative imaging technology

September 28th 2023

EyePod: Week in Review - September 17, 2023

September 23rd 2023

FDA approves RYZUMVI (Phentolamine Ophthalmic Solution) for the treatment of pharmacologically-induced mydriasis

September 27th 2023

Thea Pharma rolls out latanoprost ophthalmic solution 0.005% in the US

September 27th 2023

Kriya announces exclusive license, collaboration, agreement with Everads to advance gene therapies for diseases in ophthalmology, Including GA

September 28th 2023

EyePod: Transforming the MIGS pipeline into clinical reality

September 26th 2023

David Huang, MD, PhD, receives Lasker Award for transformative imaging technology

September 28th 2023

EyePod: Week in Review - September 17, 2023

September 23rd 2023

FDA approves RYZUMVI (Phentolamine Ophthalmic Solution) for the treatment of pharmacologically-induced mydriasis

September 27th 2023

Thea Pharma rolls out latanoprost ophthalmic solution 0.005% in the US

September 27th 2023

Related Content

Advertisement

---

Kriya announces exclusive license, collaboration, agreement with Everads to advance gene therapies for diseases in ophthalmology, Including GA

Article

---

EyePod: Transforming the MIGS pipeline into clinical reality

Podcast

---

David Huang, MD, PhD, receives Lasker Award for transformative imaging technology

Article

---

EyePod: Week in Review - September 17, 2023

Podcast

---

FDA approves RYZUMVI (Phentolamine Ophthalmic Solution) for the treatment of pharmacologically-induced mydriasis

Article

---

Thea Pharma rolls out latanoprost ophthalmic solution 0.005% in the US

Article